

This item is the archived peer-reviewed author-version of:

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin : a randomized phase II EORTC trial

Reference:

Specenier Pol, Remenar E., Buter J., Schrijvers D. L., Bergamini C., Licitra L. F., Awada A., Clement P. M., Fortpied C., Menis J.,- TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin : a randomized phase II EORTC trial
Annals of oncology / European Society for Medical Oncology - ISSN 0923-7534 - 28:9(2017), p. 2219-2224
Full text (Publisher's DOI): <https://doi.org/10.1093/ANNONC/MDX300>
To cite this reference: <http://hdl.handle.net/10067/1456500151162165141>

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.

P.M. Specenier¹, E. Remenar², J. Buter³, D. L. Schrijvers⁴, C. Bergamini⁵, L.F. Licitra⁵, A. Awada⁶, P. M. Clement⁷, C. Fortpied⁸, J. Menis⁸, J.B. Vermorken¹;

¹ Department of Oncology, Antwerp University Hospital, Edegem, Belgium and Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; ²National Institute for Oncology, Budapest, Hungary; ³Free University Medical Center, Amsterdam, The Netherlands; ⁴Hospital Network Antwerp, Belgium; ⁵IRCCS National Cancer Institute Milan, Italy; ⁶ Institute Jules Bordet, Brussels, Belgium; ⁷ Department of Oncology, Catholic University of Louvain, Louvain, Belgium; ⁸EORTC Headquarters, Brussels, Belgium

Correspondence

Prof Vermorken Jan B

Department of Oncology

Antwerp University Hospital

Wilrijkstraat 10

Edegem 2650

Belgium

32 3 8214667

JanB.Vermorken@uza.be

ABSTRACT

Background: Our aim was to test the safety of cetuximab added to chemoradiation with either cisplatin or carboplatin after prior induction chemotherapy.

Methods: Patients with stage III/IV unresectable, squamous cell carcinoma of the head and neck received up to 4 cycles of TPF-E (cisplatin and docetaxel 75 mg/m² on day 1 followed by 5-FU 750 mg/m²/day as a continuous infusion on day 1-5 plus cetuximab at a loading dose of 400 mg/m² followed by a weekly dose of 250 mg/m²), with prophylactic antibiotics but no growth factors. Patients not progressing after 4 cycles of TPF-E were randomly assigned to radiotherapy (70 Gy over 7 weeks in 2 Gy fractions) and weekly cetuximab with either weekly cisplatin 40 mg/m² or carboplatin, AUC of 1.5 mg/ml/min. Primary endpoint was feasibility.

Results: Forty-seven patients were recruited. One patient did not start TPF (hypersensitivity reaction during the cetuximab loading dose). Induction TPF-E was discontinued in 12 patients due to toxicity (6 patients), medical decision (2), death (1), patient refusal (1), protocol violation (1), co-morbidity (1). Three further patients were not randomized (progressive disease [1], protocol violation [1], toxicity and co-morbidity [1]). Of particular interest are three patients who suffered from bowel perforation, one patient who died as results of pneumonia and septic shock, and a second patient who was found dead at home 12 days after starting TPF-E (cause of death unknown).

Weekly cisplatin and carboplatin was stopped early in 7 and 4 patients, respectively.

Radiotherapy was stopped in 2 patients with cisplatin and interrupted in 1 patient with cisplatin and 4 patients with carboplatin. **Conclusions:** The addition of cetuximab to full dose TPF induction chemotherapy led to unacceptable complications and premature closing of the study. Only 34 out of 46 patients completed 4 cycles of TPF-E and only 30 started biochemoradiation.

EudraCT Number: 2006-004189-14

Key words

Head and Neck Cancer

Locoregionally advanced

Induction chemotherapy

Cetuximab

Biochemoradiation

TPF

Key Message:

The addition of cetuximab to full dose TPF induction chemotherapy in patients with locoregionally advanced head and neck cancer led to unacceptable complications and premature closing of this study. The feasibility of cetuximab plus chemoradiation with weekly cisplatin or carboplatin after prior TPF could not be demonstrated.

INTRODUCTION

Standard treatment options for patients with locoregionally advanced non-metastatic (stage III or IV) squamous cell carcinoma of the head and neck (LA-SCCHN) include surgery followed by postoperative (chemo)radiation and definitive cisplatin-based chemoradiation.[1] The addition of cetuximab to irradiation (bioradiation) is also associated with a significant improvement in locoregional control and overall survival (OS).[2, 3] The role of induction chemotherapy remains highly controversial [4-6]. The addition of a taxane to the combination of cisplatin and 5-fluoruracil (PF) consistently improved the outcome in randomized phase 3 trials.[7] The updated meta-analysis of chemotherapy in head and neck cancer (MACH-NC) suggested that induction chemotherapy and concomitant chemoradiotherapy might have complimentary effects on disease control.[8] We hypothesized that the addition of cetuximab to induction chemotherapy and chemoradiation might further improve the outcome. In order to test the feasibility and safety of such an approach, we conducted a randomized phase II trial in which two platinum-based strategies in sequential design were studied in order to select one to be used as experimental arm in a future phase III trial.

Methods

Study population

Eligibility criteria included histologically proven newly diagnosed stage III or IV unresectable non-metastatic measurable SCCHN, World Health Organisation (WHO) performance status (PS) 0 or 1, age 18-75 years, and adequate organ functions. All patients gave written informed consent. Excluded were patients with nasal, paranasal, or nasopharyngeal primaries, and patients with a history of other malignancy.

Baseline evaluation included medical history, physical examination, vital signs, WHO PS, complete blood counts, serum chemistry, urinalysis, gadolinium-enhanced magnetic resonance imaging (MRI) or contrast computed tomography (CT)-scan of the head and neck, chest X-ray with or without CT-scan, endoscopy, abdominal ultrasound or CT-scan in case of liver function test abnormalities, bone scan in case of local symptoms, electrocardiogram (ECG) and left ventricular ejection fraction (LVEF) assessment, and a baseline formalin-fixed paraffin-embedded (FFPE) tumor sample.

Treatment*Induction chemotherapy*

Patients were scheduled to receive two cycles of TPF-E every 3 weeks (cisplatin 75 mg/m² and docetaxel 75 mg/m² on day 1 followed by 5-FU 750 mg/m²/day as a continuous infusion day 1 to 5) followed by 2 additional TPF-E cycles in the absence of disease progression (PD).

Prophylactic antibiotic therapy was mandatory. Ciprofloxacin (or an alternative) was recommended at 500 mg orally bid for 10 days starting on day 5 of each cycle.

No primary prophylactic administration of granulocyte colony stimulating factor (G-CSF) was permitted. However, G-CSF was to be given prophylactically during the second and/or subsequent cycles in patients with febrile neutropenia or infection, delayed recovery of absolute neutrophil count at day 28, or grade 4 neutropenia persisting for ≥ 7 days during a prior cycle.

In case of progression at any time during induction chemotherapy patients went off-study.

Concurrent chemoradiotherapy

At the end of induction chemotherapy, patients with stable disease (SD), partial (PR) or complete response (CR) were randomized to receive either cisplatin 40 mg/m² or carboplatin AUC 1.5 mg/ml/min, administered weekly for the entire duration of the RT.

Conventionally fractionated radiotherapy (70 Gray [Gy] over 7 weeks in 2 Gy fractions) was to be started within 5 weeks from the start of the last TPF-E cycle. Standard opposed fields with a single anterior field as well as conformal techniques (3D-conventional radiotherapy and/or intensity modulated RT [IMRT]) were allowed. A simultaneous integrated boost (SIB) technique was not allowed.

Cetuximab treatment

Cetuximab was started at a loading dose of 400 mg/m² on day 1 of the first induction TPF-E cycle and thereafter administered weekly at a dose of 250 mg/m² throughout the entire treatment period (during induction chemotherapy and concurrent chemoradiotherapy).

Assessments

Physical examination including vital signs, and neurological evaluation, toxicity scoring according to CTCAE 3.0, and complete blood counts and serum chemistry were performed weekly. At the end of TPF-E cycle 2 and 4 and 3 months after end of concurrent chemoradiation, a gadolinium-enhanced MRI or CT scan of the head and neck was performed. ECG, LVEF assessment, and endoscopy were mandatory at the end of TPF-E cycle 4.

Study design

This was a randomized, open label, multi-center, phase II screening feasibility trial.

Random treatment allocation was stratified by institution and by response to TPF-E (response vs. non-response).

The primary endpoint was feasibility of the chemoradiotherapy part of the treatment, defined as at least 80% dose intensity of any of the RT, the platinum and cetuximab during that part of the treatment protocol. In order for a patient to be classified into the category where the regimen was feasible, all of the following were to be satisfied: at least 66 Gy of RT received, at least 80% relative dose intensity of RT, at least 80% relative dose intensity of the platinum (cisplatin or carboplatin) during the biochemoradiation, at least 80% relative dose intensity of cetuximab during biochemoradiation.

Any case not satisfying these criteria was counted as failing the feasibility criterion. Secondary endpoints were toxicity, dose modifications, and response rate (CR and PR).

Statistical design and analysis

The trial aimed to detect a treatment arm that had a feasibility rate of 80% among patients that could proceed to biochemoradiation. For this feasibility rate, 60% was chosen as a rate of little interest. A Sargent and Goldberg design was used. If one arm had the desired feasibility rate (80%) and the other arm had the rate of little interest (60%), there would be a 90% probability of selecting the better arm. This could be achieved by randomizing 25 patients per arm, and selecting the arm that had at least a 7% superior feasibility rate (corresponding to two more patients with feasible chemoradiotherapy out of 25). If the

difference was less than 7%, the selection had to be done according to other data, and it was assumed that in half of those cases the better arm would be chosen. If the two arms in reality had similar (but different) feasibility rates, the probability of choosing the worse arm was > 10 %. If the worst arm had a primary endpoint rate of 65% (vs. 80%), then the probability of selecting the better arm was > 85 %.

Randomization was restricted to non-progressive patients after TPF-E. Assuming a drop-out of 10 % for not reaching chemoradiotherapy, 55 patients were expected to be enrolled.

The analysis of the primary endpoint was to be conducted on the set of patients randomized into the biochemoradiation part of the study who started their allocated treatment (at least one dose of the platinum). Patients who dropped out due to toxicity or patient decision were to be counted into this population, as failures. Feasibility rates by treatment arm, with two-sided 95% exact confidence intervals were to be calculated. No direct comparisons between treatment arms other than the decision rule of the Sargent and Goldberg design were planned. Tolerability and safety were described using CTCAE 3.0 grade.

RESULTS

Between April 2008 and December 2009, 47 patients from seven institutions in Italy, Hungary, the Netherlands, and Belgium were recruited. One patient did not start TPF due to a hypersensitivity reaction during the cetuximab loading dose. The EORTC Independent Data Monitoring Committee (IDMC) recommended definitive closure of the study in May 2010 because of safety concerns during the induction part of the study.

Of the 47 patients recruited, 31 were randomized to receive either cisplatin-based (n=15) or carboplatin-based (n=15) biochemoradiation (see CONSORT flow chart, figure 1S). Baseline characteristics of the patients are shown in **table 1**.

Compliance and safety during induction chemotherapy

Thirty-four (73.9 %) patients received 4 cycles of TPF-E, while 4 (8.7 %), 6 (13 %), and 2 (4.3 %) patients received 3, 2, or 1 cycle, respectively. Treatment duration and dose intensity are summarized in table 2. Median relative dose intensity was 97.6 % for TPF-E and 102.2 % for

cetuximab. TPF-E dose and schedule modifications are summarized in **table 1S**. TPF-E was discontinued in 12 patients. Reasons for discontinuation were toxicity ($n = 6$; 1 grade 5 [febrile neutropenia, and septic shock]), protocol violation ($n = 1$), patient's best interest ($n = 2$), patient refusal ($n = 1$), death of unknown cause after the first TPF-E cycle ($n = 1$), cerebrovascular accident ($n = 1$). Three further patients were not randomized due to PD under TPF-E ($n = 1$), protocol violation ($n = 1$), and co-morbidity and toxicity issues ($n = 1$). Grade ≥ 3 toxicity during TPF-E is summarized in **table 2S**. Of particular interest are three patients who suffered from bowel perforation, one patient who died as results of pneumonia and septic shock and a second patient who was found dead at home 12 days after starting treatment with TPF-E (cause of death unknown).

Compliance and safety during chemoradiotherapy

Of the 31 patients randomized, one patient allocated to the cisplatin arm did not start biochemoradiation for toxicity reasons. One patient allocated to the carboplatin arm did not receive cetuximab during biochemoradiation (hypersensitivity reaction during induction phase). Adherence to protocol-specified therapy during biochemoradiation is summarized in **table 2**.

Dose intensity is summarized in table 3. Cisplatin and carboplatin were stopped prematurely in 7 (46.7 %) and 4 (26.6 %) patients, respectively. Cetuximab was stopped early in 4 patients (26.6%) of the carboplatin arm because of skin toxicity. Radiation was stopped prematurely in 2 patients (13.3 %) in the cisplatin arm. It was interrupted temporarily in 1 (6.7 %) and 4 (26.6 %) patients in the cisplatin and carboplatin arm, respectively. Grade ≥ 3 toxicity during biochemoradiation is summarized in **table 3S**. One patient in the cisplatin arm most likely died as result of toxicity (general physical deterioration). One patient in the carboplatin arm died due to pharyngeal bleeding 9 months after the end of biochemoradiation.

Feasibility of the biochemoradiation regimen

Of the 30 patients exposed to biochemoradiation, only 7 in the cisplatin arm (46.7%) and 8 in the carboplatin arm (53.3%) met the feasibility criteria of 80% dose intensity.

Treatment activity

Efficacy data are summarized in **table 4S** and figures 2S and 3S.

Discussion

The primary endpoint of this randomized phase II study was to test the feasibility of biochemoradiation with cetuximab and either weekly cisplatin 40 mg/m² or weekly carboplatin AUC 1.5 mg/ml/min after prior induction chemotherapy with TPF-E in association with cetuximab, a regimen which is also not yet prospectively validated. The primary objective was to select the most feasible platinum strategy in biochemoradiation after TPF-E in a future phase III trial. A total of 47 patients entered the study (instead of the 55 planned) of whom ultimately 31 after induction could be randomized for chemoradiotherapy (instead of the 50 planned). The study was stopped prematurely because of safety issues encountered during the induction biochemotherapy phase and the higher than expected drop-out rate during this induction phase. Therefore, although only 47% and 53% of patients met the feasibility criteria of 80% dose intensity in the cisplatin and carboplatin arms, respectively, a definitive conclusion on the feasibility of the biochemoradiation part of the protocol could not be made due to the high number of drop-outs (33 % of patients) before this part of the treatment.

Since the premature closing of our study, the combination of radiation, cisplatin, and cetuximab in patients with LA-HNSCC has been abandoned after the publication of the results of RTOG protocol #0522, demonstrating that the addition of cetuximab to the radiation-cisplatin platform significantly increased toxicity and did neither improve PFS nor OS. [9] In our trial, biochemoradiation was preceded by cisplatin-based induction chemotherapy, an approach that although by itself demonstrated to be feasible in large randomized phase III trials, might increase toxicity of the subsequent platinum-based chemoradiation [10-14]. Biochemoradiation preceded by induction chemotherapy was attempted by Stojan et al who planned to treat 30 patients with 4 cycles of TPF in patients with normal bone marrow, renal and hepatic function followed by RT in combination with weekly cetuximab and cisplatin, 30 mg/m², or carboplatin AUC 1.5 mg/ml.min (in case of creatinine clearance <60 mL/min and/or peripheral polyneuropathy grade >1). Only 6 patients (20%) were able to complete treatment (induction and concomitant part) according the study protocol, without interruptions and chemotherapy substitutions. [15]

Our study was closed early because of serious adverse events observed during the induction part of the protocol. In particular, the rate of febrile neutropenia and infectious events was high and the gastrointestinal adverse events were common and strikingly severe, among which three bowel perforations. Serious toxicities, in particular mucositis, infectious complications and gastrointestinal toxicities, including bleedings, have been encountered also with the American TPF regimen when given in full dose in combination with cetuximab (13). The American TPF regimen (cisplatin 100 mg/m² and docetaxel 75 mg/m², both on day 1, followed by 5-FU 1000 mg/m²/day, as a continuous infusion over 4 days) needed to be adapted when cetuximab was added. The maximum tolerated 5-FU dose in that TPF-E regimen was determined at 850 mg/m² [16]. DeLOS-II, a German multicenter randomized phase II trial in which the European TPF regimen (the regimen as used in our study) +/- cetuximab was followed by RT (69.6 Gy) with or without cetuximab in patients with resectable laryngeal and hypopharyngeal cancer, also identified 5-FU as a critical drug in the combination with regards to toxicity. Cetuximab increased particularly the non-hematologic toxicity when combined with TPF/TP versus TPF/TP alone, and very often required dose reductions in both arms [17].

Experience in Spain, again with the European TPF plus cetuximab in a similar population as in our study (50 patients, all with unresectable disease), and using prophylactic antibiotics and G-CSF support from the start, is also in line with our conclusion, i.e. that full dose TPF plus cetuximab is unacceptably toxic. They encountered grade 3/4 neutropenia in 24%, febrile neutropenia in 20%, diarrhea in 12%, infections, thrombocytopenia and hepatotoxicity (all in 4%) and hypomagnesemia in 2% with two treatment related deaths [18]

The combination of cetuximab with a platinum/taxane doublet might be better feasible, although also here the addition of cetuximab led to reduced chemotherapy doses in several trials. [19-23]

Moreover, the platinum/taxane doublets have not been compared with TPF, which is supported by multiple randomized phase III trials and by an individual patient based meta-analysis and which is therefore widely considered the induction chemotherapy regimen of choice.

We conclude that in our study the addition of cetuximab to full dose TPF induction chemotherapy in patients with unresectable locoregionally advanced HNSCC led to

unacceptable complications and premature closing of the study. Because of the high drop-out during the induction part, no definitive conclusions can be drawn about the feasibility of the biochemoradiation part of the treatment protocol. The feasibility of that part is however highly questionable, as only half of the patients received the pre-defined 80 % dose intensity level in the biochemoradiation phase. Although the addition of cetuximab to chemoradiation with cisplatin does not improve outcome overall [9], there are indications that some subgroups still might benefit from this combination [24]. Therefore further study is needed. This accounts also for biochemotherapy; optimal partnership between chemotherapy and cetuximab should be looked for based on tolerance, safety and efficacy as well as a better selection of patients who might benefit from this approach.

We acknowledge several weaknesses in our trial including the use of weekly cisplatin or carboplatin which have not been validated as standard treatment regimens and the mixing of two questions i.e. the addition of cetuximab to TPF induction chemotherapy and the addition of cetuximab to subsequent chemoradiation.

Acknowledgements:

We thank the European Organisation for Research and Treatment of Cancer Headquarters team, in particular Livia Giurgea, Ravi Karra Gurunath, Elke Neven and Thomas Valkaert.

Funding: Educational grant from Sanofi-Aventis and Merck KGaA and from the Cancer Fund (FOCA) of Belgium.

Disclosure: Jan B Vermorken received Honoraria from Merck, Amgen, Innate Pharma, Synthon, Sanofi and acted in a Consulting or Advisory role for Merck, Amgen, Innate Pharma, Synthon, PCI Biotech; the other authors have no conflicts of interests to declare

Reference List

[1] V. Gregoire, J.L. Lefebvre, L. Licitra, and E. Felip. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 21 Suppl 5 (2010) v184-v186.

- [2] J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, R.B. Cohen, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N. Engl. J. Med.* 354 (2006) 567-578.
- [3] J.A. Bonner, P.M. Harari, J. Giralt, R.B. Cohen, C.U. Jones, R.K. Sur, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol.* 11 (2010) 21-28.
- [4] P. Specenier. Induction chemotherapy in head and neck cancer: are we too ambitious? *Future. Oncol.* 10 (2014) 337-340.
- [5] P. Specenier. Induction chemotherapy in squamous cell carcinoma of the head and neck: saved by the bell? *Oral Oncol.* 51 (2015) e5-e7.
- [6] P. Specenier; J.B. Vermorken. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited? *Cancer Lett.* 256 (2007) 166-177.
- [7] P. Blanchard, J. Bourhis, B. Lacas, M.R. Posner, J.B. Vermorken, J.J. Hernandez, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. *J. Clin. Oncol.* 31 (2013) 2854-2860.
- [8] J.P. Pignon, A. Le Maître, E. Maillard, J. Bourhis, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother. Oncol.* 92 (2009) 4-14.
- [9] K.K. Ang, Q. Zhang, D.I. Rosenthal, P.F. Nguyen-Tan, E.J. Sherman, R.S. Weber, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). *J. Clin. Oncol.* 29 (2011) 5500.
- [10] D. Van Gestel, D. van den Weyngaert, G. De Kerf, B. De Ost, O. Vanderveken, C. Van Laer, et al. Helical tomotherapy in head and neck cancer: a European single-center experience. *Oncologist.* 20 (2015) 279-290.
- [11] M.J. Ahn, A. D'Cruz, J.B. Vermorken, J.P. Chen, I. Chitapanarux, H.Q. Dang, A. Guminski, et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. *Oral Oncol.* 53 (2016) 10-16.

[12] J.L. Lefebvre, Y. Pointreau, F. Rolland, M. Alfonsi, A. Baudoux, C. Sire, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPILIN randomized phase II study. *J Clin. Oncol.* 31 (2013) 853-859.

[13] M.G. Ghi, A. Paccagnella, P. D'Amanzo, C.A. Mione, S. Fasan, S. Paro, et al. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. *Int. J. Radiat. Oncol. Biol. Phys.* 59 (2004) 481-487.

[14] R. Hitt, R. Mesia, J.J. Grau, L. Iglesias, E. Del Barco, A. Lozano, et al. Randomized phase III trial of induction chemotherapy (ICT) with docetaxel-cisplatin-5-fluorouracil (DCF) followed by cisplatin-radiotherapy (CRT) or cetuximab-radiotherapy (CetRT) in patients (pts) with locally advanced unresectable head and neck cancer (LAUHNC). *J Clin. Oncol.* 34(suppl), 6001 (abstr). 2017.

[15] P. Strojan, K.C. Grasic, B. Zumer, M. Kadivec, K. Karner, I. Fajdiga, et al. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck. *Head Neck* 36 (2014) 1555-1561.

[16] R.I. Haddad, R.B. Tishler, C. Norris, L. Goguen, T.A. Balboni, R. Costello, et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. *J. Clin. Oncol.* 27 (2009) 4448-4453.

[17] A. Dietz, M. Flentje, F. Hagen, U. Bockmuehl, Koelbl, O, V. Schilling, et al. Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-fluorouracil (F) (TPF), or TP followed by concomitant boost radiotherapy (R) with or without cetuximab (E) for functional organ preservation (FOP) of resectable laryngeal and hypopharyngeal cancer (LHSCC): First results of the phase II randomized DeLOS-II study. *J.Clin.Oncol.* 32(5s). 2014.

[18] R. Mesia, S. Vazquez, J.J. Grau, J.A. Garcia-Saenz, A. Lozano, C. Garcia, J. et al. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Fluorouracil as an Induction Regimen in Patients With Unresectable

Squamous Cell Carcinoma of the Head and Neck. *Int J Radiat. Oncol. Biol. Phys.* 94 (2016) 289-296.

[19] A. Argiris, D.E. Heron, R.P. Smith, S. Kim, M.K. Gibson, S.Y. Lai, et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. *J. Clin. Oncol.* 28 (2010) 5294-5300.

[20] M.S. Kies, F.C. Holsinger, J.J. Lee, W.N. William, Jr., B.S. Glisson, H.Y. Lin, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. *J. Clin. Oncol.* 28 (2010) 8-14.

[21] K.W. Lee, Y. Koh, S.B. Kim, S.W. Shin, J.H. Kang, H.G. Wu, et al. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. *Oncologist.* 20 (2015) 1119-1120.

[22] T.Y. Seiwert, D.J. Haraf, E.E. Cohen, E.A. Blair, K. Stenson, M. Kocherginsky, et al. A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHx), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). *J.Clin.Oncol.* 29 (2011) (Suppl). 2011.

[23] H.J. Wanebo, J. Lee, B.A. Burtness, J.A. Ridge, M. Ghebremichael, S.A. Spencer, et al. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). *Ann. Oncol.* 25 (2014) 2036-2041.

[24] J.B. Weidhaas, J. Harris, D. Schaeue, A.M. Chen, R. Chin, R. Axelrod, et al. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol.* 3 (2017) 483-491.

Table 1: Patient characteristics

	All patients	TPF safety population	Chemoradiation safety population		
	<i>n</i> = 47	<i>n</i> = 46	Cisplatin <i>n</i> = 15	Carboplatin <i>n</i> = 15	Total <i>n</i> = 30
Age (years)					
Median	56.7	57	56.7	55.7	56.2
Range	48.5-71.8	48.5-71.8	48.5-68.7	48.5-71.8	48.5-71.8
	N (%)	N (%)	N (%)	N (%)	N (%)
Male/female	42/5	41/5	13/2	12/3	25/5
Stage					
III	4 (8.5)	4 (8.7)	2 (13.3)	0	2 (6.7)
IV	43 (91.5)	42 (91.3)	13 (86.7)	15 (100)	28 (93.3)
Tumor site					
oral cavity	5 (10.6)	4 (8.7)	1 (6.7)	2 (13.3)	3 (10.0)
oropharynx	24 (51.1)	24 (52.2)	8 (53.3)	8 (53.3)	16 (53.3)
hypopharynx	12 (25.5)	12 (26.1)	4 (26.7)	2 (13.3)	6 (20.0)
larynx	4 (8.5)	4 (8.7)	1 (6.7)	3 (20.0)	4 (13.3)
unknown primary	2 (4.3)	2 (4.3)	1 (6.7)	0	1 (3.3)
Reason for unresectability					
tumor size	28 (59.6)	28 (60.9)	8 (53.3)	9 (60.0)	17 (56.7)
tumor accessibility	2 (4.3)	2 (4.3)	1 (6.7)	0	1 (3.3)
infiltration adjacent structure	13 (27.7)	12 (26.1)	4 (26.7)	5 (33.3)	9 (30.0)
too mutilating	1 (2.1)	1 (2.2)	0	1 (6.7)	1 (3.3)
other	3 (6.4)	3 (6.5)	2 (13.3)	0	2 (6.7)
Performance status					
0	30 (63.8)	29 (63)	9 (60.0)	10 (66.7)	19 (63.3)
1	17 (36.2)	17 (37)	6 (40.0)	5 (33.3)	11 (36.7)
Current smoker	30 (63.8)	29 (63)	7 (46.7)	9 (60.0)	16 (53.3)
History of alcohol abuse	28 (59.6)	27 (58.7)	8 (53.3)	7 (46.7)	15 (50.0)

Table 2: Chemoradiation treatment adherence

	Cisplatin arm		Carboplatin arm	
<i>Radiation</i>				
Duration (weeks)				
Median	7		7.1	
Range	3-8.1		6.7-8.1	
Cumulative dose (Gy)				
Median	70.0		70.0	
Range	20.4-70.0		69.8-70.0	
<i>Systemic treatment</i>				
	Cisplatin	Cetuximab	Carboplatin	Cetuximab
	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
Number of administrations				
0	0	0	0	1 (6.7)
1	0	0	0	0
2	1 (6.7)	0	0	1 (6.7)
3	1 (6.7)	1 (6.7)	1 (6.7)	1 (6.7)
4	1 (6.7)	1 (6.7)	2 (13.3)	0
5	4 (26.7)	1 (6.7)	1 (6.7)	1 (6.7)
6	2 (13.3)	2 (13.3)	0	2 (13.3)
7	6 (40.0)	9 (60.0)	8 (53.3)	5 (33.3)
8	0	1 (6.7)	3 (20.0)	3 (20.0)
11	0	0	0	1 (6.7)
Cumulative dose (range)				
Unit	mg/m ² /week	mg/m ² /week	mg/ml/min/week	mg/m ² /week
Median	34.8	238.1	1.5	243.2
Range	11.0; 40.1	148.1;285.7	0.6;1.5	0;385.0

Table 3: Dose intensity during biochemoradiation

		Cisplatin arm	Carboplatin arm
Cisplatin	median	34.8	1.5
	range	11.0-40.1	0.6-1.5
Cetuximab	median	238.1	243.2
	range	148.1-285.7	0.0-385.0

cisplatin and cetuximab: mg/m²/week; carboplatin: AUC/week

Table 1S: TPF dose and schedule modifications

Drug	Treatment delayed	Dose reduction	Inappropriate dose	Interruption	Discontinuation
	Number of patients (%)				
Docetaxel	2 (4.3 %)	1 (2.2 %)			
Cisplatin	2 (4.3 %)	2 (4.3 %)	1 (2.2 %)		
5-FU	2 (4.3 %)	3 (6.5 %)		1 (2.2 %)	2 (4.3 %)
Cetuximab	12 (26.1 %)	1 (2.2 %)	3 (6.5 %)		

Table 2S: Grade ≥ 3 toxicity during induction chemotherapy

	<i>n</i> = 46		
	grade 3	grade 4	grade 5
	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
Gastrointestinal	10 (21.7)	4 (8.7)	
Constipation	2 (4.3)		
Diarrhea	1 (2.2)		
Mucositis stomatitis	3 (6.5)	1 (2.2)	
Nausea	3 (6.5)		
Vomiting	2 (4.3)		
Gastrointestinal other	4 (8.7)	3 (6.5)	
Infection	6 (13.0)	2 (4.3)	
Febrile neutropenia	3 (6.5)	1 (2.2)	
Infection with normal ANC	1 (2.2)		
Infection other	3 (6.5)	1 (2.2)	
Hematological	19 (41.3)	17 (37.0)	
Leukopenia	17 (37.0)	7 (15.2)	
Neutropenia	11 (23.9)	14 (30.4)	
Anemia	4 (8.7)		
Thrombocytopenia		1 (2.2)	
Cardiac	1 (2.2)	1 (2.2)	1 (2.2)
Sinus tachycardia		1 (2.2)	
Hypertension	1 (2.2)		
Hypotension		1 (2.2)	
Left ventricular dysfunction		1 (2.2)	
Cardiac other			1 (2.2)
Biochemistry			
Hyponatremia	9 (19.6)	1 (2.2)	
Hypokalemia	6 (13.0)	4 (8.7)	
Hypocalcemia	7 (15.2)	3 (6.5)	
Hypercalcemia		3 (6.5)	
Hypomagnesemia	6 (13.0)	5 (10.9)	
Urea	1 (2.2)		
Bilirubin	2 (4.3)		
Gammaglutamyl transferase	1 (2.2)		
Constitutional symptoms	8 (17.4)		
Fatigue	6 (13.0)		
Weight loss	1 (2.2)		
Constitutional symptoms other	2 (4.3)		
Neurological	3 (6.5)	1 (2.2)	
Dizziness	1 (2.2)		
Neurological other	2 (4.3)	1 (2.2)	
Respiratory	5 (10.9)	3 (6.5)	1 (2.2)
Pneumonitis	2 (4.3)		1 (2.2)
Respiratory other		1 (2.2)	
Renal failure	2 (4.3)		

Dermatological	4 (8.7)		
Acneiform rash	1 (2.2)		
Erythema multiforme	1 (2.2)		
Dermatological other	3 (6.5)		

Table 3S: Grade ≥ 3 toxicity during chemoradiation

	Cisplatin <i>n</i> = 15		Carboplatin <i>n</i> = 15	
	grade 3 <i>n</i> (%)	grade 4 <i>n</i> (%)	grade 3 <i>n</i> (%)	grade 4 <i>n</i> (%)
Gastrointestinal	11 (73.3)		7 (46.7)	1 (6.7)
Constipation	1 (6.7)			
Mucositis stomatitis	6 (40.0)		3 (20.0)	
Nausea	1 (6.7)			
Vomiting			2 (13.3)	
Gastrointestinal other	9 (60.0)		6 (40.0)	1 (6.7)
Infection	7 (46.7)		3 (20.0)	
Febrile neutropenia			1 (6.7)	
Infection with normal ANC	3 (20.0)		1 (6.7)	
Infection other			1 (6.7)	
Hematological	6 (40.0)	1 (6.7)	2 (13.3)	
Leukopenia	1 (6.7)		2 (13.3)	
Neutropenia	2 (13.3)			
Thrombocytopenia	1 (6.7)		1 (6.7)	
Biochemistry				
Hyponatremia	4 (26.7)			
Hypokalemia	1 (6.7)			
Hypocalcemia				
Hypercalcemia		1 (6.7)		
Hypomagnesemia	2 (13.3)	2 (13.3)	2 (13.3)	
Urea	2 (13.3)			
Constitutional symptoms				
Fatigue	3 (20.0)		1 (6.7)	
Weight loss	2 (13.3)		1 (6.7)	
Constitutional symptoms other			2 (13.3)	
Neurological	1 (6.7)		1 (6.7)	
Dizziness	1 (6.7)			
Neurological other	1 (6.7)		1 (6.7)	
Hearing loss	1 (6.7)			
Respiratory			1 (6.7)	1 (6.7)
Cough			1 (6.7)	
Respiratory other				1 (6.7)
Renal failure				
Dermatological				
Rash desquamation	1 (6.7)		1 (6.7)	
Rash dermatitis	2 (13.3)		4 (26.7)	1 (6.7)

Table 4S: Treatment activity

Response to TPF		
	<i>n</i> = 46	
	<i>n</i> (%)	
No CR/PR	9 (19.6)	
CR/PR after 2 or 4 cycles	37 (80.4)	
Response after chemoradiation		
	Cisplatin	Carboplatin
	N = 15	N = 15
CR	2 (13.3)	5 (33.3)
PR	12 (80.0)	10 (66.7)
SD	1 (6.7)	0
Progression-free survival		
Median (95% CI)	11.3 months (7.8,12.9)	
at 1 year (95 % CI)	45.2 % (29.9, NR)	
Overall survival		
Median (95% CI)	23.3 months (23.3, NR)	
at 1 year (95 % CI)	86.5% (72.3, 93.7)	




Figure 1S Consort diagram

254x190mm (96 x 96 DPI)




Figure 2 Progression-free survival

254x190mm (96 x 96 DPI)




Figure 3S Overall survival
254x190mm (96 x 96 DPI)